De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether some patients with excellent responses to
chronic myeloid leukaemia (CML) treatment are being overtreated, and can remain well on
either a lower dose of treatment or without treatment at all. The dose of imatinib (Glivec),
nilotinib (Tasigna) or dasatinib (Sprycel) treatment will initially be cut to half the
standard dose for 12 months, and then treatment will be stopped completely for a further two
years. The trial information will also help to develop a de-escalation and stopping strategy
for future newly diagnosed CML patients in the next British national CML study (to be known
as SPIRIT3).
Phase:
Phase 2
Details
Lead Sponsor:
University of Liverpool
Collaborators:
Imperial College London Newcastle University University of Glasgow